Teladoc Health (NYSE:TDOC) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts have set 12-month price targets for Teladoc Health, revealing an average target of $22.43, a high estimate of $28.00, and a low estimate of $17.00. This current average represents a 17.45% decrease from the previous average price target of $27.17.

Interpreting Analyst Ratings: A Closer Look

A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teladoc Health's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Teladoc Health analyst ratings.

Discovering Teladoc Health: A Closer Look

Unraveling the Financial Story of Teladoc Health

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Teladoc Health's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 0.04%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Teladoc Health's net margin is impressive, surpassing industry averages. With a net margin of -4.37%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Teladoc Health's ROE excels beyond industry benchmarks, reaching -1.25%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Teladoc Health's ROA stands out, surpassing industry averages. With an impressive ROA of -0.66%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.68.

The Basics of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.